Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma


Malignant peritoneal mesothelioma is a rare neoplasm. The most common type, the epithelioid type, has been further divided into histological patterns of tubulo-papillary, acinar, adenomatoid, micropapillary, or solid. Its prognosis is improved by the use of a locoregional treatment combining extensive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), which increases survival up to 50 months. Histology is one of the most important prognostic variable that, forms the basis for treatment decisions. However, the prognostic of the epithelioid type varies greatly due to its tumor heterogeneity. It is therefore necessary to find prognostic factors of malignant epithelioid peritoneal mesothelioma in order to better define the therapeutic strategy. Among histological factors, solid growth, tumor necrosis, nuclear atypia, and mitotic count were found to be independent prognostic factors in epithelioid malignant pleural mesothelioma. However, in epithelioid malignant peritoneal mesothelioma (EMPM), these factors were studied in small and heterogeneous series in terms of histological growth and definitions used for histological factors. The present large study was conducted to investigate the prognostic impact of several histologic factors in EMPM. Their prognosis impacts were assessed using overall survival (OS) and progression-free survival (PFS) in EMPM.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 15, 2022


  • Other: No intervention
    • No intervention

Arms, Groups and Cohorts

  • peritoneal malignant mesothelioma of grade 1
    • peritoneal malignant mesothelioma of grade 1
  • peritoneal malignant mesothelioma of grade 2
    • peritoneal malignant mesothelioma of grade 2
  • peritoneal malignant mesothelioma of grade 3
    • peritoneal malignant mesothelioma of grade 3

Clinical Trial Outcome Measures

Primary Measures

  • Assessment of pronostic impact of nuclear grade in comparison with combined grade in peritoneal malignant mesothelioma
    • Time Frame: 3 months to 4 years
    • Assessment by the review of pathologists

Participating in This Clinical Trial

Inclusion Criteria

  • – peritoneal malignant mesothelioma Exclusion Criteria:

  • opposition to reuse personnal data

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.